MVX-ONCO-1 phase 1 final results of the first personalized cell-based immunotherapy using cell encapsulation technology

被引：10
|
作者：
Mach, N. [1 ]
Vernet, R. [1 ]
Belkouch, M-C. [1 ]
Luy, P. [1 ]
Ancrenaz, V. [1 ]
Teta, P. [1 ]
Blazek, N. [1 ]
Grandjean, N. [1 ]
Wasem, J. [1 ]
Grogg, J. [2 ]
Perez, T. [2 ]
Migliorini, D. [1 ]
机构：
[1] HUG, Oncol, Geneva, Switzerland
[2] MaxiVAX SA, Clin Operat, Geneva, Switzerland
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw378.12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1058P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Dendritic cell-based immunotherapy in combination with programmed cell death 1 blockade reduced established tumors by activating Th-1 type immune responses in a murine hepatocellular carcinoma model
    Hayashi, Eiichi
    Eguchi, Junichi
    Sakaki, Masashi
    Doi, Hiroyoshi
    Oomori, Risa
    Kajiwara, Atsushi
    Yoshida, Hitoshi
    Ishii, Shigeaki
    Hiroishi, Kazumasa
    Imawari, Michio
    CANCER RESEARCH, 2014, 74 (19)
  • [42] Using adaptive genetic algorithms combined with high sensitivity single cell-based technology to detect bladder cancer in urine and provide a potential noninvasive marker for response to anti-PD1 immunotherapy
    Alanee, Shaheen
    Deebajah, Mustafa
    Chen, Pin-, I
    Mora, Rodrigo
    Guevara, Jose
    Francisco, Brian
    Patterson, Bruce K.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (03) : 77.e9 - 77.e15
  • [43] Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay
    Normandin, Karine
    Lavallee, Jean-Francois
    Futter, Marie
    Beautrait, Alexandre
    Duchaine, Jean
    Guiral, Sebastien
    Marinier, Anne
    Archambault, Vincent
    SCIENTIFIC REPORTS, 2016, 6
  • [44] Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay
    Karine Normandin
    Jean-François Lavallée
    Marie Futter
    Alexandre Beautrait
    Jean Duchaine
    Sébastien Guiral
    Anne Marinier
    Vincent Archambault
    Scientific Reports, 6
  • [45] Development of a Cell-Based AAV9 Vector Potency Assay for the GAN Phase 1 Clinical Trial
    Bailey, Rachel M.
    Zaric, Violeta
    Grieger, Joshua C.
    Samulski, R. Jude
    Gray, Steven J.
    MOLECULAR THERAPY, 2017, 25 (05) : 125 - 126
  • [46] Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma
    Rizell, Magnus
    Eilard, Malin Sternby
    Andersson, Mats
    Andersson, Bengt
    Karlsson-Parra, Alex
    Suenaert, Peter
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [47] INACTIVATED, CELL-BASED YELLOW FEVER 17D VACCINE-SAFETY AND IMMUNOGENICITY IN ANIMAL MODELS AND RESULTS OF A PHASE 1 CLINICAL TRIAL
    Monath, Thomas P.
    Lee, Cynthia K.
    Julander, Justin G.
    Brown, Alicja
    Beasley, David W.
    Hayman, Edward
    Crowell, Joseph
    Morin, Merribeth
    Fowler, Elizabeth
    Johnson, Casey
    Chen, Lin H.
    Sisti, Maggie
    Trent, Dennis W.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2010, 83 (05): : 16 - 16
  • [48] Towards a cell-based treatment for androgenetic alopecia in men and women: 12-month interim safety results of a phase 1/2a clinical trial using autologous dermal sheath cup cell injections
    McElwee, K.
    Panich, D.
    Hall, D.
    Hoffmann, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 (05) : 1401 - 1401
  • [49] Screening and isolation of a natural dopamine D1 receptor antagonist using cell-based assays
    Yu, Sungryul
    Park, Jeong Soo
    Paredes, Verenice
    Song, Myoung-Chong
    Baek, Nam-In
    Lee, Sang-Ik
    Lim, Jong-Soon
    Cho, Nam-Young
    Yoon, Jaeseung
    Baek, Kwanghee
    JOURNAL OF BIOTECHNOLOGY, 2010, 145 (03) : 304 - 309
  • [50] Using a beta-lactamase reporter system for the CYP1A1 induction in a cell-based HTS assay format
    Trubetskoy, OV
    Marks, BD
    Printen, J
    DRUG METABOLISM REVIEWS, 2003, 35 : 86 - 86
12345